Promise and pitfalls of molecular markers of thyroid nodules

Thyroid nodules are common in the general population with a prevalence of 5-7% The initial evaluation of thyroid nodules commonly involves thyroid function tests, an ultrasound (USG) and fine needle aspiration biopsy (FNAB). The optimal management of patients with thyroid nodules with indeterminate cytology is plagued by the lack of highly sensitive and specific diagnostic modalities In this article we attempt to review the available literature on the molecular markers which are increasingly being studied for their diagnostic utility in assessing thyroid nodules. The various molecular markers consist of gene mutations, gene re arrangements, RNA based assays and immunohistochemical markers. The molecular markers definitely would help to optimise the management of such patients.

[1]  E. Alexander,et al.  Diagnostic use of molecular markers in the evaluation of thyroid nodules. , 2012, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[2]  Darya Chudova,et al.  Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. , 2012, The New England journal of medicine.

[3]  M. Zeiger,et al.  The quest for diagnostic molecular markers for thyroid nodules with indeterminate or suspicious cytology , 2012, Journal of surgical oncology.

[4]  S. T. Dunn,et al.  Cytologic and molecular diagnosis of thyroid cancers , 2012, Cancer cytopathology.

[5]  R. Seethala,et al.  Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. , 2011, The Journal of clinical endocrinology and metabolism.

[6]  R. Valcavi,et al.  Is a five‐category reporting scheme for thyroid fine needle aspiration cytology accurate? Experience of over 18 000 FNAs reported at the same institution during 1998–2007 , 2011, Cytopathology : official journal of the British Society for Clinical Cytology.

[7]  R. Paschke,et al.  Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. , 2011, The Journal of clinical endocrinology and metabolism.

[8]  M. Xing,et al.  Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. , 2010, Thyroid : official journal of the American Thyroid Association.

[9]  H. Gharib,et al.  AACE / AME / ETA Guidelines AMERICAN ASSOCIATION Of ClINICAl ENDOCRINOlOgISTS , ASSOCIAzIONE MEDICI ENDOCRINOlOgI , AND EuROPEAN ThyROID ASSOCIATION MEDICAl guIDElINES fOR ClINICAl PRACTICE fOR ThE DIAgNOSIS AND MANAgEMENT Of ThyROID NODulES , 2010 .

[10]  C. Croce,et al.  Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. , 2010, Endocrine-related cancer.

[11]  F. Pacini,et al.  Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. , 2010, The Journal of clinical endocrinology and metabolism.

[12]  Xuguang Zhu,et al.  Lessons from mouse models of thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[13]  Yuri E Nikiforov,et al.  Molecular diagnostics and predictors in thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[14]  M. Nikiforova,et al.  Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. , 2009, The Journal of clinical endocrinology and metabolism.

[15]  G. Tseng,et al.  MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. , 2008, The Journal of clinical endocrinology and metabolism.

[16]  M. Santoro,et al.  Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.

[17]  Manjula K. Gupta,et al.  Thyroid-stimulating hormone receptor messenger ribonucleic acid measurement in blood as a marker for circulating thyroid cancer cells and its role in the preoperative diagnosis of thyroid cancer. , 2007, The Journal of clinical endocrinology and metabolism.

[18]  R. Camp,et al.  ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  V. Vasko,et al.  Specific pattern of RAS oncogene mutations in follicular thyroid tumors. , 2003, The Journal of clinical endocrinology and metabolism.

[20]  J. Garber,et al.  Genetic and biological subgroups of low-stage follicular thyroid cancer. , 2003, The American journal of pathology.

[21]  M. Nikiforova,et al.  PAX8-PPAR&ggr; Rearrangement in Thyroid Tumors: RT-PCR and Immunohistochemical Analyses , 2002, The American journal of surgical pathology.

[22]  G. Fuller,et al.  RET Oncogene Activation in Papillary Thyroid Carcinoma , 2001, Advances in anatomic pathology.

[23]  C. Cheung,et al.  Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. , 2001, The Journal of clinical endocrinology and metabolism.

[24]  Channing J Der,et al.  Increasing complexity of Ras signaling , 1998, Oncogene.

[25]  S. Hirohashi,et al.  Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. , 1991, Oncogene.